The Wolff Parkinson White Syndrome Market is projected to reach USD 1.65 Billion by 2030 at 5.2% CAGR during the forecast period 2024-2030.
Wolff-Parkinson-White (WPW) syndrome is a rare congenital heart disorder involving irregularities in the electrical transmission system of the heart. In WPW syndrome, an abnormal alternate electrical pathway exists resulting in arrhythmias (abnormal heartbeat rhythms) and tachycardia (faster than normal heartbeats). WPW is congenital but, symptoms may not become apparent until adolescent. Approximately 10 to 20 % of individuals with WPW syndrome have a congenital heart defect, such as Ebstein’s anomaly. The disorder’s estimated prevalence is -3 people per 1,000 people in the United States.
May 2021: Boston Scientific Corporation's CE Mark approval for EXAL Model B Single-Use Bronchoscope, a disposable tool intended for bedside procedures in the ICU, OR, and bronchoscopy suite, was obtained.
Medtronic declared in January 2021 that its temperature-controlled irrigation radiofrequency ablation system (TCIRFAS) with diamonds has been cleared by the FDA for paroxysmal atrial fibrillation refractory to medications.
This is the smallest pacemaker in the world, and it provides atrioventricular (AV) synchrony, which is known as the Micra AV Transcatheter Pacing System (TPS). It got approved by Medtronic plc in June 2020 with a CE (Conformite Europeenne) Mark.
January 2021: the FDA gave permission to Medtronic to use its temperature-controlled irrigation radiofrequency ablation system with diamonds on patients who have paroxysmal atrial fibrillation and are not responding to drug treatment.
Abbott Laboratories launched this nonsurgical occluder, Amplatzer Piccolo Occluder, named after it. The Indian medical device company’s product was designed specifically for premature babies that needed nonsurgical closure of patent ductus arteriosus (PDA) defects. This carefully crafted Amplatzer Piccolo Occluder fills the lacuna for a minimally invasive approach to PDA; it closes PDAs specifically occurring among preterms. What is more impressive is that it can be employed even in neonates weighing just about 700 grams and as young as three days old.
The symptoms associated with WPW syndrome are irregular heartbeats especially supraventricular tachycardia, palpitations, dyspnea, chest pain, fatigue, atrial flutter, ventricular fibrillation, atrial fibrillation,anxiety, dizziness etc. These symptoms may result in cardiac arrest and sudden death.
The exact cause of WPW syndrome is unknown however genetic mutations and abnormal genes are the most suspected causes. WPW syndrome is often present at birth (congenital), but may not be detected until adolescence or later. Peak incidence has been reported in individuals between 30 and 40 years old in otherwise healthy adults.
The market drivers for Wolff Parkinson White syndrome are increasing screening for genetic diseases, rising awareness and growing income of people etc. The market restraints can be poor cure rates, poor efficacy and effectiveness drugs etc.
Key Players in the Wolff Parkinson White syndrome Market Some of key players profiled in the report are
Intended Audience
The global Wolff Parkinson White syndrome market has been segmented on the basis of types, diagnosis, treatment and end users.
Based on types, the market has been segmented as type A and type B.
Based on diagnosis, the market has been segmented as Electrocardiogram (ECG), Electrophysiological testing, and others.
Based on treatment, the market has been segmented as drugs, cardioversion, radiofrequency catheter ablation, surgery, artificial pacemaker and others.
Based on the end users, the market has been segmented as hospitals & clinics, academic & research and others.
Regional analysis:
The Americas which are dominated by the US account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new instruments and surgical techniques in the US drives the Wolff Parkinson White syndrome market. The good reimbursement scenario and the greater awareness in the developed regions drive the Wolff Parkinson White syndrome Market.
Europe is the second largest market in the world due to high income and healthcare penetration. The European region is dominated by Germany and France. The presence of large screening programs in the developed regions drives the market for Wolff Parkinson White syndrome.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Research Methodology:
The report for Wolff Parkinson White syndrome market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
| Report Attribute/Metric | Details |
| Market Size | USD 1,659.9 Million |
| CAGR | 5.2% |
| Base Year | 2023 |
| Forecast Period | 2024-2030 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease type, Diagnosis, Treatment, End Users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | AngioDynamics, Medtronic, Boston Scientific Corporation, St. Jude Medical, LLC, Abbott, GlaxoSmithKline LLC, Teva Pharmaceutical Industries, Sanofi S.A., and Novartis International AG, and others. |
| Key Market Opportunities | extensive use of medications and high expenditure on the health care |
| Key Market Drivers | · Increasing number of hospitals · Greater awareness |
Frequently Asked Questions (FAQ) :
The Wolff Parkinson white syndrome market is projected to grow at a 5.2% CAGR between 2024-2030.
The Americas is expected to dominate the Wolff Parkinson white syndrome market.
The Wolff Parkinson white syndrome market is predicted to touch USD 1,659.9 Million by 2030.
Some common symptoms of Wolff Parkinson white syndrome include chest pain, palpitation, fatigue, and others.
Poor efficacy of drugs may limit the Wolff Parkinson white syndrome market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
